LON:APTA

Aptamer Group Interim Earnings Results & Report

Aptamer Group logo
GBX 0.30 -0.02 (-6.77%)
As of 11/18/2026 12:16 PM Eastern

Aptamer Group reported Interim earnings on March 11, 2025. The company reported EPS of GBX 0.07.

Earnings Announcement Details

Quarter
Interim
Report Date

Aptamer Group EPS Results

Actual EPS
GBX 0.07
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Aptamer Group Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Aptamer Group Interim Earnings FAQ

Aptamer Group (LON:APTA) reported earnings of GBX 0.07 per share for Interim. The report was announced on Tuesday, March 11, 2025.

Aptamer Group Earnings Headlines

Top Trader Reveals Stunning Black Friday Deal
Others paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.tc pixel
Aptamer Group Regulatory News
Aptamer Group PLC
See More Aptamer Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aptamer Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aptamer Group and other key companies, straight to your email.

About Aptamer Group

Aptamer Group (LON:APTA) is a leading provider of aptamer selection services and developer of aptamer-based reagents for use in research, bioprocessing, diagnostic, and therapeutic applications. Headquartered in York, UK, the Company partners globally to deliver aptamer-based solutions that drive discovery and development across the life sciences. Aptamer Group has developed the proprietary Optimer® platform technology that drives three distinct businesses: Aptamer Solutions, Aptamer Diagnostics and Aptamer Therapeutics. Through the use of its Optimer platform the Company aims to enable new opportunities, including discovery and development partnerships for improved biologic drugs, and new applications, such as novel assays and targets, to accelerate discovery and improve current standard processes. For more information, visit: https://aptamergroup.com/

View Aptamer Group Profile